Drug intelligence / Profile preview

VNPP595

Development stage: Preclinical
Lead developer: Isoprene Pharmaceuticals
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules

Overview

VNPP595 is a preclinical-stage small molecule developed by Isoprene Pharmaceuticals as a backup compound within their targeted protein degradation pipeline. It is characterized as a non-Cereblon molecular glue degrader. Based on its classification within the VNPP series (which includes the lead compound VNPP433-3β), VNPP595 is designed to target the androgen receptor (AR), its splice variants such as AR-V7, and the E3 ubiquitin ligase MDM2. The compound's mechanism involves inducing the degradation of these oncogenic proteins to overcome resistance mechanisms in advanced cancers, particularly castration-resistant prostate cancer (CRPC).

Targets

AR (Adrenergic receptors)MDM2 (Mouse double minute 2 homolog)

Beyond the preview

Go deeper on VNPP595.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VNPP595.

Explore the full profile